Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Dynavax Projects HEPLISAV-B Inflection In 2019, While CEO Eddie Gray Continues To Search For SD-101 Partners [Seeking Alpha]

Dynavax Technologies Corporation (DVAX)  More Company Research Source: Seeking Alpha
Last dynavax technologies corporation earnings: 3/11 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dynavax.com
PDF Dynavax Projects HEPLISAV-B Inflection In 2019, While CEO Eddie Gray Continues To Search For SD-101 PartnersSummaryDynavax recently presented a company outlook for 2019 at the JP Morgan Healthcare Conference. During the presentation, CEO Eddie Gray revealed encouraging HEPISLAV-B sales for Q4 of ~$3.7M.2018 was a big year for Dynavax's lead immuno-oncology candidate SD-101. The company has stated they are looking for a potential partner for their planned Phase III in melanoma.The stock experienced a strong sell-off in Q4, but the new year has treated DVAX well so far. I review the charts and identify key areas for investors. [Read more]
Impact snapshot Event time: DVAX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
DVAX alerts

from News Quantified
Opt-in for
DVAX alerts

from News Quantified